Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-31001074; ketoconazole · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| JNJ-31001074; ketoconazole | DRUG | - |
Inclusion Criteria: * healthy volunteer between the ages of 18-55 * if a woman, must be of non childbearing potential (ie, post menopausal or surgically sterile) and have a negative pregnancy test * body mass index between 18-30 * body weight greater than or equal to 50 kilograms * blood pressure b...
JNJ-31001074 is an investigational small molecule being studied in healthy volunteers for pharmacokinetics and drug interactions. It was evaluated in a Phase 1 clinical trial to assess its interaction with ketoconazole. The drug is not approved and remains in clinical development.
The molecular target of JNJ-31001074 has not been disclosed. It is a small molecule being studied for its pharmacokinetic properties and potential drug interactions in healthy volunteers. No specific target or mechanism of action has been reported for this investigational compound.
JNJ-31001074 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The compound is an investigational small molecule that has been studied in early-stage clinical trials.
JNJ-31001074 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized study in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
JNJ-31001074 has been studied in one completed clinical trial, NCT00915746, titled 'A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers.' This Phase 1 study enrolled 14 participants and evaluated the drug's pharmacokinetics and interaction with ketoconazole.
No, JNJ-31001074 is not the same as ketoconazole. JNJ-31001074 is an investigational small molecule being developed by Johnson & Johnson, while ketoconazole is an antifungal medication. The two were studied together in a clinical trial to assess potential drug interactions.